The Natural History of Primary Inner Ear Schwannomas: Outcomes of Long-Term Follow-Up.


Journal

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504

Informations de publication

Date de publication:
01 12 2022
Historique:
pubmed: 23 9 2022
medline: 15 11 2022
entrez: 22 9 2022
Statut: ppublish

Résumé

To describe the natural history of primary inner ear schwannomas over a long follow-up period. Retrospective case series. Tertiary referral center. Patients with primary inner ear schwannomas with serial audiometric and radiologic follow-up. Patterns of hearing loss, rate of hearing decline, presence of vestibular symptoms, and rate of tumor growth. A total of 12 patients with 13 tumors were identified. The mean duration of follow-up was 7 years. Forty-six percent of tumors were intracochlear, 15% were intravestibular, 23% were transmodiolar, and 15% were intravestibular-cochlear. Hearing loss was the most common presenting symptom, occurring in all patients. Among patients with serviceable hearing (American Academy of Otolaryngology-Head and Neck Surgery Class A or B) at the time of presentation, the average time to decline to a nonserviceable hearing level was 57.3 months (range, 21-117 mo). Hearing loss was sudden in 31% of patients, progressive in 61% and fluctuating in 8%. No patients had intractable vertigo; however, two required vestibular physiotherapy. On initial magnetic resonance imaging, the mean largest tumor dimension was 3.1 mm (standard deviation, 1.2 mm), and the mean largest dimension on most recent magnetic resonance imaging was 4.4 mm (standard deviation, 1.1 mm). Two tumors exhibited no growth over a follow-up of 11.3 and 2.8 years, respectively. Overall, the mean growth was 0.25 mm per year followed. Two patients underwent cochlear implantation with simultaneous tumor resection and had favorable outcomes. Long-term follow-up suggests a conservative approach, with possible hearing rehabilitation at the time of deterioration, is a safe management strategy for primary inner ear schwannomas.

Identifiants

pubmed: 36136609
doi: 10.1097/MAO.0000000000003698
pii: 00129492-202212000-00041
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1168-e1173

Informations de copyright

Copyright © 2022, Otology & Neurotology, Inc.

Déclaration de conflit d'intérêts

Sources of support and disclosure of funding : This study did not receive any funding from external sources. D.J. receives grant money from Advanced Bionics and is a consultant for Cochlear Corp. J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. There are no direct conflicts of interest related to the current study.

Références

Dubernard X, Somers T, Veros K, et al. Clinical presentation of intralabyrinthine schwannomas: a multicenter study of 110 cases. Otol Neurotol 2014;35:1641–9.
Santos F, Linthicum FH, House JW, Wilkinson EP. Histopathologic markers of hearing loss in intralabyrinthine schwannomas: implications for management. Otol Neurotol 2011;32:1542–7.
Neff BA, Willcox TO Jr., Sataloff RT. Intralabyrinthine schwannomas. Otol Neurotol 2003;24:299–307.
Marinelli JP, Lohse CM, Carlson ML. Incidence of intralabyrinthine schwannoma: a population-based study within the United States. Otol Neurotol 2018;39:1191–4.
Choudhury B, Carlson ML, Jethanamest D. Intralabyrinthine schwannomas: disease presentation, tumor management, and hearing rehabilitation. J Neurol Surg B Skull Base 2019;80:196–202.
Van Abel KM, Carlson ML, Link MJ, et al. Primary inner ear schwannomas: a case series and systematic review of the literature. Laryngoscope 2013;123:1957–66.
Salzman KL, Childs AM, Davidson HC, et al. Intralabyrinthine schwannomas: imaging diagnosis and classification. AJNR Am J Neuroradiol 2012;33:104–9.
Kennedy RJ, Shelton C, Salzman KL, Davidson HC, Harnsberger HR. Intralabyrinthine schwannomas: diagnosis, management, and a new classification system. Otol Neurotol 2004;25:160–7.
Campos Paiva AL, de Salles AA, Diniz JM, et al. Gamma knife radiosurgery for transmodiolar schwannoma. World Neurosurg 2020;143:118–20.
Massager N, Drogba L, Delbrouck C, et al. Gamma knife radiosurgery for intralabyrinthine schwannomas. J Radiosurg SBRT 2011;1:237–45.
Bento RF, Gebrim EM, Magalhães AT, Pereira LV, Fonseca AC. Minimally invasive surgery for intracochlear schwannoma removal and simultaneous cochlear implantation. Int Arch Otorhinolaryngol 2016;20:271–4.
Carlson ML, Neff BA, Sladen DP, Link MJ, Driscoll CL. Cochlear implantation in patients with intracochlear and intralabyrinthine schwannomas. Otol Neurotol 2016;37:647–53.
Plontke SK, Rahne T, Pfister M, et al. Intralabyrinthine schwannomas : surgical management and hearing rehabilitation with cochlear implants. HNO 2017;65(Suppl 2):136–48.
Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg 1995;113:179–80.
Bouchetemblé P, Heathcote K, Tollard E, et al. Intralabyrinthine schwannomas: a case series with discussion of the diagnosis and management. Otol Neurotol 2013;34:944–51.
Lee SU, Bae YJ, Kim HJ, et al. Intralabyrinthine schwannoma: distinct features for differential diagnosis. Front Neurol 2019;10:750.
Garcia JM, Urquijo DP, Puerta M, et al. Cochlear implant in patients with single sided deafness: hearing results and communicative benefits. Cochlear Implants Int 2020;21:136–44.
Aschendorff A, Arndt S, Laszig R, et al. Treatment and auditory rehabilitation of intralabyrinthine schwannoma by means of cochlear implants: English version. HNO 2017;65(Suppl 1):46–51.
Patel EJ, Deep NL, Friedmann DR, et al. Cochlear implantation in sporadic vestibular schwannoma and other retrocochlear pathology: a case series. Otol Neurotol 2021;42:e425–32.

Auteurs

Zain Khera (Z)

New York University Grossman School of Medicine.

Emily Kay-Rivest (E)

Division of Otology and Neurotology, Department of Otolaryngology-Head and Neck Surgery, New York University Langone Health, New York, New York.

David R Friedmann (DR)

Division of Otology and Neurotology, Department of Otolaryngology-Head and Neck Surgery, New York University Langone Health, New York, New York.

Sean O McMenomey (SO)

Division of Otology and Neurotology, Department of Otolaryngology-Head and Neck Surgery, New York University Langone Health, New York, New York.

J Thomas Roland (J)

Division of Otology and Neurotology, Department of Otolaryngology-Head and Neck Surgery, New York University Langone Health, New York, New York.

Daniel Jethanamest (D)

Division of Otology and Neurotology, Department of Otolaryngology-Head and Neck Surgery, New York University Langone Health, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH